Faculty introduction and disclosures

Introductory content  Statistics and prognosis Pathophysiology R/R FL clinical features The role of progression of disease within 24 months as a prognostic indicator

Treatment of R/R FL Present and investigational pharmacotherapy, clinical trial findings, guideline updates, and sequencing of therapy, including the roles of:  o   Immunotherapy and chemoimmunotherapy o   Lenalidomide with anti-CD20 therapy o    T-cell engager therapy: bispecific antibody therapy, chimeric antigen receptor T-cell therapy  o   Targeting B-cell signaling: EZH2 inhibition, BTK inhibition Patient cases

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Recall the epidemiology, diagnosis, and cytogenetics of R/R FL.
• Summarize the efficacy of existing and anticipated roles of late stage investigational management strategies in R/R FL.
• Formulate a treatment plan for a patient R/R FL.

ACCME Activity #202792517

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosures of Faculty: Eric Tam, MD, Assistant Professor of Clinical Medicine, Keck Medicine of USC, has no relevant financial disclosures.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.  

Faculty WILL NOT discuss off-label uses of a commercial product. 

All relevant financial relationships have been mitigated. 

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This activity is supported by an educational grant from BeiGene. 

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version